Sectors
DNTH
Dianthus Therapeutics, Inc.
103.99
2 x 74.42
2 x 131.99
bid
ask
-
1.85
1.75%
02:08 PM
timesize
| Ytd | 152.34% | |
| 1y | 341.20% |
102.38
day range
106.00
23.39
52 week range
117.88
| Open | 105.34 | Prev Close | 105.84 | Low | 102.38 | High | 106.00 | Mkt Cap | 5.82B |
| Vol | 173.02K | Avg Vol | 1.05M | EPS | -4.24 | P/E | N/A | Forward P/E | -22.31 |
| Beta | 1.22 | Short Ratio | 10.01 | Inst. Own | 128.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 103.35 | 200-d Avg | 74.28 | 1yr Est | 137.62 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -1.02 | N/A | N/A | N/A |
| 2026-08-04 | 2026-06 | -0.85 | -0.9 | -0.05 | -6.35% |
| 2026-05-05 | 2026-03 | -1.17 | -0.85 | 0.32 | 27.35% |
| 2026-03-09 | 2025-12 | -0.98 | -1.43 | -0.45 | -45.92% |
| 2025-11-05 | 2025-09 | -0.86 | -0.97 | -0.11 | -12.79% |
| 2025-08-07 | 2025-06 | -0.86 | -0.88 | -0.02 | -2.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-06 | Truist Securities | Upgrade | Buy | Buy |
| 2026-08-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-05 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-03 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-06 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-09 | Wolfe Research | Upgrade | Outperform |
Profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-11 | CARR EDWARD | Officer | 0.00 | Conversion of Exercise of derivative security |
| 2026-08-06 | GARCIA MARINO | Chief Executive Officer | 65.29K | Conversion of Exercise of derivative security |
| 2026-08-09 | MCGEORGE ANNE | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-05-31 | RANDHAWA SIMRAT | Officer | 4.00K | Conversion of Exercise of derivative security |
| 2026-08-18 | READ SIMON J. | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-07-08 | SAVITZ RYAN | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 8.20M | 867.88M | 15.00% |
| 2026-06-29 | Blackrock Inc. | 4.12M | 436.47M | 7.54% |
| 2026-06-29 | T. Rowe Price Investment Management, Inc. | 3.89M | 411.55M | 7.11% |
| 2026-06-29 | Wellington Management Group, LLP | 3.23M | 341.85M | 5.91% |
| 2026-06-29 | Fairmount Funds Management LLC | 2.54M | 268.54M | 4.64% |
| 2026-06-29 | Price (T.Rowe) Associates Inc | 2.51M | 266.18M | 4.60% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.59M | 168.51M | 2.91% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.57M | 165.69M | 2.86% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.30M | 137.39M | 2.37% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.24M | 131.72M | 2.28% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.21M | 128.55M | 2.22% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 730.06K | 77.27M | 1.34% |